Aaron Kesselheim
Harvard University
H-index: 75
North America-United States
Top articles of Aaron Kesselheim
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Characteristics of Patients Receiving Novel Muscular Dystrophy Drugs in Trials vs Routine Care | JAMA Network Open | Dongzhe Hong Jerry Avorn Richard Wyss Aaron S Kesselheim | 2024/1/2 |
Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis | JAMA neurology | John Kim Aaron S Kesselheim Riley Bove Jerry Avorn Benjamin N Rome | 2024/1/1 |
Federal Oversight of Laboratory-Developed Tests. Reply. | The New England Journal of Medicine | Udit Singhal Aaron S Kesselheim Todd M Morgan | 2024/2/1 |
Administrative action on drug pricing: Lessons and opportunities for the Center for Medicare and Medicaid Innovation | Journal of Managed Care & Specialty Pharmacy | Ian TT Liu Hussain S Lalani Aaron S Kesselheim | 2024/3/1 |
The FDA in the Crosshairs-Science, Politics, and Abortion. | JAMA | AS Kesselheim | 2024/3/25 |
Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies | JAMA oncology | Ariadna Tibau Thomas J Hwang Consolacion Molto Jerry Avorn Aaron S Kesselheim | 2024/4/4 |
How health technology assessment can help to address challenges in drug repurposing: a conceptual framework | Teebah Abu-Zahra Sabine E Grimm Mirre Scholte Adam JN Raymakers Aaron S Kesselheim | 2024/4/30 | |
Why Some Patients Overpay for Specialty Generic Drugs | JAMA Internal Medicine | Francis J Crosson Aaron S Kesselheim | 2024/1/1 |
March-In Guidance For Publicly Funded Drugs: A Necessary Safety Net For Patients | Health Affairs Forefront | Jerry Avorn Aaron S Kesselheim | 2024 |
Independent Advice on Drug Approvals: an Investigation of EMA Practices | Journal of General Internal Medicine | C Joseph Ross Daval Aaron S Kesselheim Leigh Sharpless Ameet Sarpatwari | 2024/2 |
Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition | JAMA | Ameet Sarpatwari Sajeev Kohli S Sean Tu Aaron S Kesselheim | 2024/2/22 |
Characterizing first-& second-generation follow on drugs: Clinical trial & development timelines of Bruton tyrosine kinase (BTK) inhibitors | Cancer Research | Ashwin Varma William B Feldman Aaron S Kesselheim Edward R Cliff | 2024/3/22 |
Spending on Targeted Therapies for Duchenne Muscular Dystrophy | jama | Liam Bendicksen Aaron S Kesselheim Benjamin N Rome | 2024/4/2 |
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label | Annals of Internal Medicine | Alexander C Egilman Aaron S Kesselheim Ameet Sarpatwari Benjamin N Rome | 2024/4/30 |
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone–Salmeterol to Treat Chronic Obstructive Pulmonary Disease | Annals of Internal Medicine | William B Feldman Aaron S Kesselheim Jerry Avorn Massimiliano Russo Shirley V Wang | 2024/1 |
Preserving Timely Generic Drug Competition with Legislation on “Skinny Labeling” | Clinical Pharmacology & Therapeutics | S Sean Tu Aaron S Kesselheim | 2024/1 |
Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa | JAMA dermatology | Adam JN Raymakers Aaron S Kesselheim Arash Mostaghimi William B Feldman | 2024/1/31 |
How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians | Clinical Pharmacology & Therapeutics | Ameet Sarpatwari Zhigang Lu Massimiliano Russo Heidi Zakoul Su Been Lee | 2024/2/20 |
Leah Z. Rand, Daniel P. Carpenter, Aaron S. Kesselheim, Anushka Bhaskar, Jonathan J. Darrow, and William B. Feldman Reply | Hastings Center Report | Leah Z Rand Daniel P Carpenter Aaron S Kesselheim Anushka Bhaskar Jonathan J Darrow | 2024/3 |
Use of efficiency frontiers to align prices and clinical benefits of biologic therapies for plaque psoriasis | JAMA dermatology | Alexander C Egilman Aaron S Kesselheim Jerry Avorn Adam JN Raymakers Benjamin N Rome | 2024/4/1 |
